Retired Couple With $1.4 Million Pays $0 Tax on a $52,000 Stock Gain. The Window Closes Dec. 31
Quick Read Retirees filing jointly can realize up to $96,700 in long-term gains at a 0% federal rate, but unused […]
Featured
Titan International (TWI) Signs ITM Sale. How Much of the $285 Million is New Cash?
Titan International, Inc. (NYSE:TWI) announced a definitive agreement on September 21 to sell its Italtractor ITM undercarriage business to USCO
NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has cleared a major regulatory hurdle. On September 21, it announced European Commission approval of
Interparfums (IPAR) Extends Cavalli Fragrance Deal Through 2046. Can it Boost Profits?
Interparfums, Inc. (NASDAQ:IPAR) and Marquee Brands announced on September 17 that their exclusive worldwide fragrance license for Roberto Cavalli and
Hudson Technologies (HDSN) Signs Icorium Deal. Can Better Refrigerant Recycling Lift Margins?
Hudson Technologies, Inc. (NASDAQ:HDSN) announced on September 17 that it had signed a joint development agreement with Icorium to commercialize
Churchill Downs (CHDN) Prices $500 Million Loan. Could Interest Costs Rise?
Churchill Downs Incorporated (NASDAQ:CHDN) priced a $500 million senior secured term loan due in 2033 on September 17. The borrowing
Atlanticus Holdings (ATLC) Sells Auto Finance Unit. Can it Replace Lost Earnings?
Atlanticus Holdings Corporation (NASDAQ:ATLC) announced September 17 that it had completed the sale of CAR, its entire Auto Finance segment,
Shopify shares jump 8% as Meta’s Muse AI agent adds Shop Pay checkout
Shopify (NYSE: SHOP) shares rose roughly 8% on 22 September 2026 after Meta’s Muse AI agent gained the ability to
Leonardo DRS (DRS) Wins Korean Warship Contract. Can More Orders Follow?
Leonardo DRS, Inc. (NASDAQ:DRS) announced September 17 that it had signed a contract with Doosan Enerbility to supply electric propulsion
Innate Pharma (IPHA) Closes Sobi Deal. Can the New Funding Keep Drug Trials on Track?
Innate Pharma S.A. (NASDAQ:IPHA) reported a €19.6 million first-half net loss on September 17, following the closing of its lacutamab